251 286 - Biotech Bayern

Contact:
Silvia Schmidt
Hanauerstr. 1
D-80992 München
Phone: +49 (0) 89 149096 1600
Fax: +49 (0) 89 149096 2000
E-Mail: silvia.schmidt@amgen.com
Internet: www.onkologie.de
Contact:
Gabriele Wilde
Josef-Engert-Str. 9
D-93053 Regensburg
Phone: +49 (0) 941 465-20000
Fax: +49 (0) 941 465-20100
E-Mail: gwilde@amgen.com
Internet: www.amgen.de
Contact:
Dr. Lars Wassill
Werkstr. 2
D-83555 Gars-Bahnhof
Phone: +49 (0) 8073 91693-0
Fax: +49 (0) 8073 91693-33
E-Mail: info@amplexdiagnostics.de
Internet: www.amplexdiagnostics.de
40
AMGEN GmbH
BIOTECH THERAPEUTICS & DIAGNOSTICS
Keywords: Drug Development
Amgen's corporate mission is to be the world leader in developing and
delivering important, cost-effective therapeutics based on cellular and molecular
biology. The company's first product, EPOGEN® (Epoetin alfa), stimulates
and regulates the production of red blood cells. Amgen's second product,
NEUPOGEN® (Filgrastim), is a recombinant granulocyte colony-stimulating factor
(G-CSF) that selectively stimulates growth of infection-fighting white blood cells
known as neutrophils. In 2001 Amgen launched a new drug, called Aranesp®,
which also stimulates the production of red blood cells. Aranesp® was created
by rational drug design and has a threefold longer halflife time compared to
Epogen®. In 2002 AMGEN launched a second generation G-CSF called Neulasta®
which also stimulates the growth of neutrophils. Neulasta® has an important
advantage. Due to its pegylation Neulasta® has a longer half-life time and
therefore has to be administered only once per chemotherapy cycle whereas
Neupogen® has to be administered daily.
Amgen Research GmbH
PHARMA & CHEMICAL INDUSTRY
Keywords: Drug Development, Small Molecules, Diabetics, Hematology,
Inflammation, Neurology, Oncology
AMGEN, (Applied Molecular Genetics Inc.) was founded in 1980 as one of the
pioneers of industrial biotechnology. The company develops, produces and
sells biopharmaceutical products that are produced through recombinant DNA
technologies. AMGEN Research GmbH was founded in Regensburg in 2000.
Basic research is conducted with the aim of identifying new pharmaceutical lead
structures for the development of innovative drugs. Low molecular weight
compounds are identified by high throughput screening (HTS) procedures. Over
10 million compounds are analyzed every year.
AmplexDiagnostics GmbH – Gesellschaft für
molekularbiologische Diagnostik
BIOTECH DNA/PROTEIN ANALYTICS
Keywords: Clinical Diagnostics, PCR, Infectious Diseases
AmplexDiagnostics GmbH is a privately held company for the development and
production of In Vitro Diagnostics. Our aim is the improvement of the potential
of the PCR-technology by implementing the main advantages of this technology
into the diagnosis of bacterial infections. Founded in 2002 – Amplex developed
its first product (hyplex StaphyloResist) and entered the market already in 2003.
Additional systems (hyplex STD ID for detection of sexually transmitted mycoplasms;
hyplex EHEC for detection of EHEC/EPEC and hyplex EnteroResist for characterisation
of VRE) followed in 2006. Additionally, we developed the first PCR-system
(hyplex ESBL ID) for the direct detection of ESBL producing bacteria direct from
patient material. For further information please visit www.hyplex.info or contact us.